Iris Reyhan1, Olga S Zhukov2, Robert J Lagier2, Robert F Bridgforth2, Gary J Williams2, Joanna M Popov2, Stanley J Naides3, Andreas Reiff4. 1. University of Southern California-Children's Hospital of Los Angeles, 4650 Sunset Blvd. Mailstop #60, Los Angeles, CA, 90027, USA. irisreyhan@gmail.com. 2. , 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA. 3. , 33072 Sunharbor, Dana Point, CA, 92629, USA. 4. University of Southern California-Children's Hospital of Los Angeles, 4650 Sunset Blvd. Mailstop #60, Los Angeles, CA, 90027, USA.
Abstract
BACKGROUND: Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14-3-3η in different types of JIA. METHODS: JIA patients (n = 151) followed by the Pediatric Rheumatology Core at Children's Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+; n = 39), PJIA RF- (n = 39), psoriatic arthritis (PsA; n = 19), enthesitis-related arthritis (ERA; n = 18), and oligoarticular JIA (OJIA [control group]; n = 36). RF, CCP antibody, and 14-3-3η were measured for all patients. 14-3-3η serum levels > 0.2 ng/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71). RESULTS: Elevated 14-3-3η levels were detected in 34/151 (23%) patients, and across all groups tested. Most patients with 14-3-3η had titers ≥4 times above the cutoff value. The majority (22, 65%) of 14-3-3η-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all 3, and 12 (35%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14-3-3η was not significantly associated with disease activity or age at diagnosis. CONCLUSION: Serum 14-3-3η can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14-3-3η does not appear to correlate with disease activity in JIA.
BACKGROUND: Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14-3-3η in different types of JIA. METHODS: JIA patients (n = 151) followed by the Pediatric Rheumatology Core at Children's Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+; n = 39), PJIA RF- (n = 39), psoriatic arthritis (PsA; n = 19), enthesitis-related arthritis (ERA; n = 18), and oligoarticular JIA (OJIA [control group]; n = 36). RF, CCP antibody, and 14-3-3η were measured for all patients. 14-3-3η serum levels > 0.2 ng/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71). RESULTS: Elevated 14-3-3η levels were detected in 34/151 (23%) patients, and across all groups tested. Most patients with 14-3-3η had titers ≥4 times above the cutoff value. The majority (22, 65%) of 14-3-3η-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all 3, and 12 (35%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14-3-3η was not significantly associated with disease activity or age at diagnosis. CONCLUSION: Serum 14-3-3η can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14-3-3η does not appear to correlate with disease activity in JIA.
Authors: Walter P Maksymowych; Gilles Boire; Dirkjan van Schaardenburg; Stephanie Wichuk; Samina Turk; Maarten Boers; Katherine A Siminovitch; Vivian Bykerk; Ed Keystone; Paul Peter Tak; Arno W van Kuijk; Robert Landewé; Desiree van der Heijde; Mairead Murphy; Anthony Marotta Journal: J Rheumatol Date: 2015-07-15 Impact factor: 4.666
Authors: Lennart Bertilsson; Boel Andersson-Gäre; Anders Fasth; Ingemar F Petersson; Helena Forsblad-D'elia Journal: J Rheumatol Date: 2013-02-15 Impact factor: 4.666
Authors: Walter P Maksymowych; Stanley J Naides; Vivian Bykerk; Katherine A Siminovitch; Dirkjan van Schaardenburg; Maarten Boers; Robert Landewé; Désirée van der Heijde; Paul-P Tak; Mark C Genovese; Michael E Weinblatt; Edward C Keystone; Olga S Zhukov; Rania W Abolhosn; Joanna M Popov; Karin Britsemmer; Arno W van Kuijk; Anthony Marotta Journal: J Rheumatol Date: 2014-08-15 Impact factor: 4.666
Authors: Lauren Fitzpatrick; K Alaine Broadaway; Lori Ponder; Sheila T Angeles-Han; Kirsten Jenkins; Kelly Rouster-Stevens; Christina F Pelajo; Karen Conneely; Michael P Epstein; Jorge Lopez-Benitez; Larry B Vogler; Sampath Prahalad Journal: J Rheumatol Date: 2016-02-15 Impact factor: 4.666
Authors: Marian H van Beers-Tas; Anthony Marotta; Maarten Boers; Walter P Maksymowych; Dirkjan van Schaardenburg Journal: Arthritis Res Ther Date: 2016-04-01 Impact factor: 5.156
Authors: Nathalie Carrier; Anthony Marotta; Artur J de Brum-Fernandes; Patrick Liang; Ariel Masetto; Henri A Ménard; Walter P Maksymowych; Gilles Boire Journal: Arthritis Res Ther Date: 2016-02-01 Impact factor: 5.156